In SCA3 patients, IGF-1 reduced the SARA score after 8 months of treatment but unfortunately worsened the SARA score after 20 months of treatment during a 2-year trial [9]. The gene discussed is IGF1; the disease is Spinocerebellar ataxia type 3.